FI865159A - Kompositioner som innehaoller en stabiliserad aktivator foer maenniskans vaevnadsplasminogen. - Google Patents

Kompositioner som innehaoller en stabiliserad aktivator foer maenniskans vaevnadsplasminogen. Download PDF

Info

Publication number
FI865159A
FI865159A FI865159A FI865159A FI865159A FI 865159 A FI865159 A FI 865159A FI 865159 A FI865159 A FI 865159A FI 865159 A FI865159 A FI 865159A FI 865159 A FI865159 A FI 865159A
Authority
FI
Finland
Prior art keywords
stabilizers
splasminogen
mainness
activators
composition
Prior art date
Application number
FI865159A
Other languages
English (en)
Other versions
FI88873C (fi
FI865159A0 (fi
FI88873B (fi
Inventor
William Franklin Bennett
Stuart Elliot Builder
Larry Alan Gatlin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205495&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI865159(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI865159A0 publication Critical patent/FI865159A0/fi
Publication of FI865159A publication Critical patent/FI865159A/fi
Application granted granted Critical
Publication of FI88873B publication Critical patent/FI88873B/fi
Publication of FI88873C publication Critical patent/FI88873C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI865159A 1985-12-17 1986-12-17 Foerfarande foer framstaellning av kompositioner som innehaoller stabiliserad human vaevnadsplasminogenaktivator FI88873C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81108185 1985-12-17
US06/811,081 US4777043A (en) 1985-12-17 1985-12-17 Stabilized human tissue plasminogen activator compositions

Publications (4)

Publication Number Publication Date
FI865159A0 FI865159A0 (fi) 1986-12-17
FI865159A true FI865159A (fi) 1987-06-18
FI88873B FI88873B (fi) 1993-04-15
FI88873C FI88873C (fi) 1993-07-26

Family

ID=25205495

Family Applications (1)

Application Number Title Priority Date Filing Date
FI865159A FI88873C (fi) 1985-12-17 1986-12-17 Foerfarande foer framstaellning av kompositioner som innehaoller stabiliserad human vaevnadsplasminogenaktivator

Country Status (23)

Country Link
US (2) US4777043A (fi)
EP (1) EP0228862B1 (fi)
JP (2) JPH0714886B2 (fi)
KR (1) KR950010322B1 (fi)
AT (1) ATE79273T1 (fi)
AU (1) AU600246B2 (fi)
DD (1) DD255477A5 (fi)
DE (2) DE3642960A1 (fi)
DK (1) DK174203B1 (fi)
ES (1) ES2044840T3 (fi)
FI (1) FI88873C (fi)
FR (1) FR2591485B1 (fi)
GB (1) GB2184354B (fi)
GR (1) GR3006078T3 (fi)
HU (1) HU200101B (fi)
IE (1) IE59060B1 (fi)
IL (1) IL80904A (fi)
MY (1) MY102185A (fi)
NO (1) NO168988C (fi)
NZ (1) NZ218612A (fi)
PH (1) PH24716A (fi)
PT (1) PT83933B (fi)
ZA (1) ZA869457B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE83153T1 (de) * 1985-09-10 1992-12-15 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
ES2045167T5 (es) * 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
DE19606551C2 (de) * 1996-02-22 2000-06-08 Basotherm Gmbh rt-PA zur Prävention des Nachstars nach Kataraktoperation
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
JP2003507388A (ja) * 1999-08-17 2003-02-25 ノボ ノルディスク アクティーゼルスカブ 凍結乾燥したケーキの安定化
PT1226269E (pt) 1999-11-04 2003-11-28 Genentech Inc Ensaio de hplc de fase reversa para activadores de plasminogenio
MXPA02009485A (es) * 2000-03-31 2003-03-10 Kirin Brewery Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento.
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20110179558A1 (en) * 2009-07-29 2011-07-28 International Enviroguard Systems, Inc. Breathable Protective Fabric and Garment
CA2902547A1 (en) * 2013-03-14 2014-09-25 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
DE3273732D1 (en) * 1982-12-30 1986-11-20 Kowa Co Method of producing a tissue plasminogen activator and composition comprising same
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
DE3682104D1 (de) * 1985-04-22 1991-11-28 Genentech Inc Plasminogenaktivator-mutante des menschlichen gewebes, verfahren und zwischenprodukte dafuer und diese mutante verwendende zusammensetzungen.
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
AU569429B2 (en) * 1985-05-28 1988-01-28 Wellcome Foundation Limited, The Aqueous acidic tissue plasminogen activator parenternal formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
ATE83153T1 (de) * 1985-09-10 1992-12-15 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
JPS62283932A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤

Also Published As

Publication number Publication date
ATE79273T1 (de) 1992-08-15
IE59060B1 (en) 1993-12-15
EP0228862A2 (en) 1987-07-15
JPS62164632A (ja) 1987-07-21
DK174203B1 (da) 2002-09-16
NO168988C (no) 1992-04-29
FI88873C (fi) 1993-07-26
FI865159A0 (fi) 1986-12-17
US4908205A (en) 1990-03-13
JPH07173076A (ja) 1995-07-11
ES2044840T3 (es) 1994-01-16
FR2591485B1 (fr) 1989-07-28
GR3006078T3 (fi) 1993-06-21
GB8629981D0 (en) 1987-01-28
DE3686410D1 (de) 1992-09-17
FR2591485A1 (fr) 1987-06-19
DE3642960A1 (de) 1987-06-19
PT83933A (en) 1987-01-01
ZA869457B (en) 1988-08-31
NO865079D0 (no) 1986-12-16
GB2184354B (en) 1990-04-11
MY102185A (en) 1992-04-30
HUT42955A (en) 1987-09-28
IE863279L (en) 1987-06-17
NO168988B (no) 1992-01-20
DE3686410T2 (de) 1993-02-18
US4777043A (en) 1988-10-11
IL80904A (en) 1992-01-15
GB2184354A (en) 1987-06-24
DK605786A (da) 1987-06-18
EP0228862B1 (en) 1992-08-12
AU600246B2 (en) 1990-08-09
KR950010322B1 (ko) 1995-09-14
KR870005647A (ko) 1987-07-06
HU200101B (en) 1990-04-28
EP0228862A3 (en) 1988-09-28
DD255477A5 (de) 1988-04-06
NZ218612A (en) 1989-07-27
FI88873B (fi) 1993-04-15
JPH0714886B2 (ja) 1995-02-22
IL80904A0 (en) 1987-03-31
NO865079L (no) 1987-06-18
PT83933B (pt) 1989-01-17
PH24716A (en) 1990-10-01
DK605786D0 (da) 1986-12-16
AU6661086A (en) 1987-06-18

Similar Documents

Publication Publication Date Title
FI865159A (fi) Kompositioner som innehaoller en stabiliserad aktivator foer maenniskans vaevnadsplasminogen.
IT1226726B (it) Composti attivi come inibitori della biosintesi del colesterolo.
GR3006630T3 (fi)
GR3006506T3 (fi)
DK302288A (da) Vaevsplasminogenaktivator med modificeret kringledomaene
NO882454D0 (no) Plasminogen-aktivator.
PT91584A (pt) Processo para a preparacao de uma composicao farmaceutica util para imunossupressao contendo um inibidor-activador de plasminogenio (pai-2)
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
MY102026A (en) Antiasthmatic.
ES2039251T3 (es) Tratamiento del cabello.
AU1235288A (en) Antidepressant compositions
TR22867A (tr) Birden fazla aktif bilesen ihtiva eden insektisid terkibi
GR3003132T3 (en) Pharmaceutical compositions having healing activity
ATE33552T1 (de) Dermatologische praeparate.
KR880012237A (ko) 트롬빈 제제의 제조방법
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
BR1100888A (pt) Variantes de ativador de plasminogênios de tecido, composições e métodos de uso da mesma
SE7906637L (sv) Koccidioskontroll
DK558188D0 (da) Acetylerede pseudoammoniak-, pseudourinstof- eller guanidinderivater, egnede som aktivatorer for oxiderende blegemidler
DK239084A (da) 2-alkylthio-1-aminoalkyl-2-pyrrolin-3-carbonitriler

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: GENENTECH, INC.

MA Patent expired